MGRM Monogram Technologies Inc

SOUTH SAN FRANCISCO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM) announced today that Christine A. White, M.D. has been appointed to the company's board of directors. "Christine White brings to our board a wealth of experience in oncology, as a practicing oncologist as well as several years in clinical development and medical affairs in oncology drug development," said William D. Young, Monogram's Chairman and Chief Executive Officer. "With the recent launch of the HERmark(TM) Breast Cancer Assay and with several additional assays in our development pipeline, I am delighted to have the counsel of an experienced oncologist on our board." "Monogram is breaking new and important ground with its VeraTag(TM) assay platform," said Christine White, M.D. "There is a clear need for such technologies to guide the selection of treatment regimens for cancer patients and I am excited to be joining Monogram's board at this pivotal time in the commercialization of VeraTag assays." Dr. White held a number of executive positions in medical affairs with Biogen Idec from 1996 through 2005, where she most recently served as senior vice president, global medical affairs. At Biogen Idec Dr. White played a key role in the clinical development, regulatory affairs and commercialization of both Rituxan(R) and Zevalin(R). Previously Dr. White served as director of clinical oncology research from 1994 to 1996 at the Sidney Kimmel Cancer Center in San Diego, California, and from 1984-1994 was on staff at Scripps Memorial Hospitals, La Jolla and Encinitas, California, where she was medical director of oncology research (1990-1994) and Chair of the Department of Medicine (1994). Dr. White received her medical degree from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology. Dr. White is a past member and Chair of the California Breast Cancer Research Program's Advisory Council and currently serves on the editorial boards of several peer reviewed scientific publications, including Cancer Biotherapy and Radiopharmaceuticals, Expert Review of Anticancer Therapy and Journal of Immunotherapy. Dr. White serves on the board of directors of Pharmacyclics, Inc., Arena Pharmaceuticals and Apoptos, Inc. The company also reported that it had increased the authorized size of its board of directors from six to seven. About Monogram Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/. Forward Looking Statements Certain statements in this press release are forward-looking. These forward-looking statements include references to the ability of the HERmark assay to predict response to Herceptin or to significantly improve the information available to physicians, results of studies intended to demonstrate clinical utility of HERmark, and potential commercialization of the HERmark assay or other VeraTag assays. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance of our products, including HERmark; the risk that our VeraTag assays, including HERmark may not predict response to Herceptin or other therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional HERmark or VeraTag studies; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; actual market acceptance of our products for patient use; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. VeraTag and HERmark are trademarks of Monogram Biosciences, Inc. Rituxan is a registered trademark of Biogen Idec Inc. Zevalin is a registered trademark of Cell Therapeutics, Inc. contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624 4576 Tel: 415 677-2700 amerriweather@ jeremiah.hall@ monogrambio.com fkhealth.com DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial Officer, +1-650-624-4576, ; or Jeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700, Web site: http://www.monogrambio.com/

Copyright